SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

Marketing GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride Month By Andrea Park Jun 26, 2025 3:31pm LGBTQ+ Diversity Novo Nordisk Novartis ...

The stock performance of BBAI has been tumultuous. It skyrocketed seven-fold from below $1.50 in July of the previous year to over $10 in early 2025 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are ... which is more than double the S&P 500's performance over the same time frame. However, the ...

GSK Stock Performance GSK stock opened at $38.66 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...